CL2017001857A1 - Derivado de pirazolo [3,4-d] pirimidin y su uso para el tratamiento de leishmaniasis - Google Patents

Derivado de pirazolo [3,4-d] pirimidin y su uso para el tratamiento de leishmaniasis

Info

Publication number
CL2017001857A1
CL2017001857A1 CL2017001857A CL2017001857A CL2017001857A1 CL 2017001857 A1 CL2017001857 A1 CL 2017001857A1 CL 2017001857 A CL2017001857 A CL 2017001857A CL 2017001857 A CL2017001857 A CL 2017001857A CL 2017001857 A1 CL2017001857 A1 CL 2017001857A1
Authority
CL
Chile
Prior art keywords
treatment
leishmaniasis
pyrazolo
pyrimidin
derivative
Prior art date
Application number
CL2017001857A
Other languages
English (en)
Inventor
Timothy James Miles
Michael George Thomas
Original Assignee
Glaxosmithkline Ip Dev Ltd
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Univ Dundee filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2017001857A1 publication Critical patent/CL2017001857A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>EL COMPUESTO 3,3,3-TRIFLUORO-N-((1,4-TRANS)-4-((3-((S)-2-METILMORFOLINO)-1H-PIRAZOLO[3,4- D]PIRIMIDIN-6-IL)AMINO)CICLOHEXIL)PROPANO-1-SULFONAMIDA, QUE TIENE LA FÓRMULA (I), O UNA SAL DEL MISMO, SU ENANTIÓMERO OPUESTO, COMPOSICIONES QUE COMPRENDEN EL COMPUESTO, Y SU USO EN EL TRATAMIENTO O PREVENCIÓN DE LEISHMANIASIS, EN PARTICULAR, LEISHMANIASIS VISCERAL.</p>
CL2017001857A 2015-01-23 2017-07-18 Derivado de pirazolo [3,4-d] pirimidin y su uso para el tratamiento de leishmaniasis CL2017001857A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382011 2015-01-23

Publications (1)

Publication Number Publication Date
CL2017001857A1 true CL2017001857A1 (es) 2018-02-16

Family

ID=52395018

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001857A CL2017001857A1 (es) 2015-01-23 2017-07-18 Derivado de pirazolo [3,4-d] pirimidin y su uso para el tratamiento de leishmaniasis

Country Status (26)

Country Link
US (1) US10253028B2 (es)
EP (1) EP3247713B1 (es)
JP (1) JP6625649B2 (es)
KR (1) KR102572178B1 (es)
CN (1) CN107406452B (es)
AR (1) AR103474A1 (es)
AU (1) AU2016208528B2 (es)
BR (1) BR112017015828B1 (es)
CA (1) CA2973432C (es)
CL (1) CL2017001857A1 (es)
CO (1) CO2017007135A2 (es)
CR (1) CR20170339A (es)
DO (1) DOP2017000167A (es)
EA (1) EA032763B1 (es)
ES (1) ES2754803T3 (es)
IL (1) IL253427B (es)
MX (1) MX373647B (es)
MY (1) MY190895A (es)
PE (1) PE20180020A1 (es)
PH (1) PH12017501307B1 (es)
SG (1) SG11201705626QA (es)
TW (1) TWI726861B (es)
UA (1) UA120385C2 (es)
UY (1) UY36525A (es)
WO (1) WO2016116563A1 (es)
ZA (1) ZA201704586B (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706754B2 (en) * 2000-11-06 2004-03-16 The United States Of America As Represented By The Secretary Of The Army Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
EP1880791A1 (en) 2006-07-21 2008-01-23 Aleris Aluminum Koblenz GmbH Process and apparatus for laser joining two components through the use of a laminar inert gas flow coaxial to a metal filler wire
WO2008039359A2 (en) * 2006-09-25 2008-04-03 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
US20100298557A1 (en) * 2006-12-28 2010-11-25 Taisho Pharmaceutical Co., Ltd Pyrazolopyrimidine compound
EP2108019A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases
EP3613743B1 (en) * 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
AU2009242279B2 (en) * 2008-04-29 2012-08-30 Novartis Ag Spiro-indole derivatives for the treatment of parasitic diseases
US20120165309A1 (en) * 2009-02-12 2012-06-28 Astellas Pharma Inc. Hetero ring derivative
ES2627428T3 (es) * 2009-07-02 2017-07-28 Sanofi Nuevos derivados de 2,3-dihidro-1H-imidazo{1,2-a}pirimidin-5-ona, su preparación y su utilización farmacéutica
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
SI3527563T1 (sl) * 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK

Also Published As

Publication number Publication date
AR103474A1 (es) 2017-05-10
SG11201705626QA (en) 2017-08-30
CA2973432A1 (en) 2016-07-28
ZA201704586B (en) 2019-12-18
EP3247713B1 (en) 2019-08-28
JP2018502887A (ja) 2018-02-01
US10253028B2 (en) 2019-04-09
MX2017009525A (es) 2018-04-10
UY36525A (es) 2016-08-31
EP3247713A1 (en) 2017-11-29
MX373647B (es) 2020-04-21
EA201791658A1 (ru) 2017-11-30
JP6625649B2 (ja) 2019-12-25
EA032763B1 (ru) 2019-07-31
PH12017501307A1 (en) 2018-01-29
AU2016208528A1 (en) 2017-07-27
PH12017501307B1 (en) 2018-01-29
UA120385C2 (uk) 2019-11-25
TWI726861B (zh) 2021-05-11
US20170369496A1 (en) 2017-12-28
WO2016116563A1 (en) 2016-07-28
IL253427B (en) 2019-07-31
DOP2017000167A (es) 2017-09-15
MY190895A (en) 2022-05-18
CA2973432C (en) 2023-04-04
CN107406452B (zh) 2019-07-23
AU2016208528B2 (en) 2019-02-21
CR20170339A (es) 2018-01-22
ES2754803T3 (es) 2020-04-20
KR20170104611A (ko) 2017-09-15
IL253427A0 (en) 2017-09-28
BR112017015828A2 (pt) 2018-04-24
BR112017015828B1 (pt) 2020-02-18
TW201632524A (zh) 2016-09-16
CN107406452A (zh) 2017-11-28
KR102572178B1 (ko) 2023-08-28
PE20180020A1 (es) 2018-01-09
CO2017007135A2 (es) 2017-12-15
NZ733953A (en) 2024-04-26

Similar Documents

Publication Publication Date Title
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CL2016002970A1 (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo.
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
EA201791467A1 (ru) Водный офтальмологический раствор
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
EP3292119A4 (en) DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
CL2017002449A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX374705B (es) Composiciones que comprenden anakinra.
CO2020003134A2 (es) Moduladores de la expresión de enac
PH12019500237A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
CL2017001857A1 (es) Derivado de pirazolo [3,4-d] pirimidin y su uso para el tratamiento de leishmaniasis
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.